<DOC>
	<DOCNO>NCT02698566</DOCNO>
	<brief_summary>This multicenter study design evaluate usability Lucentis prefilled syringe ( PFS ) participant neovascular age relate macular degeneration macular edema secondary retinal vein occlusion .</brief_summary>
	<brief_title>A Study Participants With Neovascular Age Related Macular Degeneration Macular Edema Secondary To Retinal Vein Occlusion Evaluate Usability LucentisÂ® Prefilled Syringe</brief_title>
	<detailed_description>The purpose study assess ability health care provider ( HCPs ) follow instruction use ( IFU ) prepare administer Lucentis PFS ITV injection dose patient .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ocular Study eye deem indicated ranibizumab ITV therapy discretion retina specialist Concurrent Ocular Conditions Participants legally blind one eye History current clinically relevant intraocular inflammation ocular inflammatory reaction ( grade trace great exclude ) , include noninfectious uveitis uveitis , sterile inflammatory reaction past ITV injection agent Active disorder ocular adnexa skin study eye , include ocular surface infection History current indication excessive bleeding recurrent hemorrhage , include prior excessive intraocular ( include subconjunctival ) bleeding hemorrhage ITV injection intraocular procedure Uncontrolled intraocular pressure great ( &gt; ) 25 millimeter mercury ( mmHg ) study eye ( uncontrolled mean occurs even intraocular pressurelowering therapy ) Use therapy know toxic ocular tissue within 6 month prior enrollment Prior Ocular Therapies Treatment ITV injection within 27 day prior Day 1 Any invasive intraocular surgery , prior longacting therapeutic agent , ocular drug release device implantation ( approved investigational ) study eye time past 3 month General Receipt systemic ( nonocular ) investigational drug within 3 month prior Day 1 Current systemic coagulation bleed disorder history recurrent hemorrhage Intolerance know reaction prior biological therapy History diseases physical laboratory examination finding per retina specialist represent contraindication ranibizumab use patient may represent unwarranted patient risk . Uncontrolled hypertension ( systolic &gt; 160 mmHg and/or diastolic &gt; 100 mmHg sit ) Current systemic infectious disease therapy active infectious disease Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>